Envestnet Portfolio Solutions
REGN icon

Envestnet Portfolio Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

Envestnet Portfolio Solutions’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$728K Sell
943
-1,252
-57% -$959K ﹤0.01% 752
2025
Q4 		$1.69M Buy
2,195
+12
+0.5% +$8.15K 0.01% 585
2025
Q3 		$1.23M Buy
2,183
+14
+0.6% +$7.92K ﹤0.01% 674
2025
Q2 		$1.14M Buy
2,169
+398
+22% +$222K ﹤0.01% 747
2025
Q1 		$1.12M Sell
1,771
-913
-34% -$628K ﹤0.01% 756
2024
Q4 		$1.91M Buy
2,684
+713
+36% +$598K 0.01% 678
2024
Q3 		$2.07M Buy
1,971
+279
+16% +$310K 0.01% 649
2024
Q2 		$1.78M Buy
1,692
+104
+7% +$101K 0.01% 667
2024
Q1 		$1.53M Buy
1,588
+400
+34% +$380K 0.01% 716
2023
Q4 		$1.04M Buy
1,188
+370
+45% +$305K ﹤0.01% 785
2023
Q3 		$673K Buy
+818
New +$643K ﹤0.01% 865

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Envestnet Portfolio Solutions's REGN Position: Q1 2026 in Review

Envestnet Portfolio Solutions reduced its Regeneron Pharmaceuticals (REGN) stake by 57% in Q1 2026, selling an estimated $959K and leaving 943 shares worth $728K. The position accounts for ﹤0.01% of the portfolio, ranked #752.

Envestnet Portfolio Solutions first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $2.07M in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Envestnet Portfolio Solutions held 943 shares of Regeneron Pharmaceuticals worth $728K as of Q1 2026.
  • Envestnet Portfolio Solutions sold 1,252 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $959K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Envestnet Portfolio Solutions's portfolio in Q1 2026, its #752 holding.
  • Envestnet Portfolio Solutions first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Envestnet Portfolio Solutions's Regeneron Pharmaceuticals position peaked at $2.07M in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Envestnet Portfolio Solutions's 13F filing for Q1 2026, filed 29 Apr 2026.